← FDA DRUG APPROVALS

FDA ANDA · ANDA074430

DESIPRAMINE HYDROCHLORIDE

Sponsor: ACTAVIS TOTOWA

APPLICATION
ANDA074430
TYPE
ANDA
ORIGINAL APPROVAL
1996-02-09
LATEST ACTION
2024-09-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

DESIPRAMINE HYDROCHLORIDEPrescription
DESIPRAMINE HYDROCHLORIDE 10MG · TABLET · ORAL
DESIPRAMINE HYDROCHLORIDEPrescription
DESIPRAMINE HYDROCHLORIDE 150MG · TABLET · ORAL

Approval history

2024-09-06Labeling · Supplement 22 · standardAP
2020-01-21Labeling · Supplement 19 · standardAP
2015-01-05Labeling · Supplement 17 · standardAP
2010-03-25Labeling · Supplement 13AP
2007-11-28Labeling · Supplement 11AP
2007-11-28Labeling · Supplement 10AP
2006-05-19Labeling · Supplement 9AP
2005-08-04Labeling · Supplement 8AP
2000-02-02Manufacturing (CMC) · Supplement 5AP
1999-04-07Manufacturing (CMC) · Supplement 2AP
1998-12-09Manufacturing (CMC) · Supplement 3AP
1998-12-09Manufacturing (CMC) · Supplement 1AP
1998-12-09Manufacturing (CMC) · Supplement 4AP
1996-02-09OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →